How much funding has Generation Bio raised?

Generation Bio has raised $235.0M in total funding, most recently a Series C round.

Who are Generation Bio's investors?

Generation Bio's investors include Atlas Venture, T. Rowe Price, Farallon Capital, Wellington Management, Foresite Capital.

When was Generation Bio founded?

Generation Bio was founded in 2016.

Where is Generation Bio headquartered?

Generation Bio is headquartered in Cambridge, Massachusetts, United States.

What industry is Generation Bio in?

Generation Bio operates in Biotech, Healthcare.

How many employees does Generation Bio have?

Generation Bio has 51-200 employees.

Generation Bio

IPO

Cambridge, United States · Founded 2016 · $235.0M raised

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2016
Business Model: B2B

Website: generationbio.com
Total Funding: $235.0M
Last Round: $110.0M Series CJan 2020
Rounds: 3

About

Generation Bio is a biotechnology company that developed a T cell-selective cell-targeted lipid nanoparticle (ctLNP) platform to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company went public and subsequently underwent a phased restructuring before being acquired by XOMA Royalty in February 2026. Its ctLNP delivery system achieved the first-ever selective delivery of siRNA to T cells in non-human primates.

Summary

Generation Bio is a Biotech company based in Cambridge, United States, founded in 2016. It has raised $235.0M in total across 3 rounds, most recently a $110.0M Series C round in Jan 2020. Investors include Atlas Venture, T. Rowe Price and Farallon Capital.